Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - Eli Lilly's new drug, Migalastat, has received approval from the National Medical Products Administration (NMPA) in China for the treatment of moderate to severe active Crohn's disease (CD) and ulcerative colitis (UC) in adults. This drug selectively inhibits the IL-23 pathway, which is involved in immune inflammatory responses [5]. - The pharmaceutical sector experienced a slight decline of -0.32% on February 11, 2025, underperforming the CSI 300 index by 0.10 percentage points, ranking 22nd among 31 sub-industries [4]. - Notable stock performances included Teva Biopharmaceuticals (+6.01%), ZhenDe Medical (+5.87%), and Keyuan Pharmaceutical (+5.79%) on the gainers' list, while Huakang Clean (-5.28%), Hualan Biologicals (-5.11%), and Qianyuan Pharmaceutical (-4.67%) led the decliners [4]. Sub-industry Summary - Chemical Pharmaceuticals: No rating [3] - Traditional Chinese Medicine: No rating [3] - Biopharmaceuticals II: Neutral [3] - Other Pharmaceutical Industries: Neutral [3]

Policy Developments - The National Health Commission and 10 other departments jointly issued the "National Basic Drug Directory Management Measures," which revises six key areas, including legal policy basis, directory structure optimization, management mechanism improvement, emphasis on clinical value, dynamic adjustment mechanism, and monitoring and evaluation enhancement [1][2]. Drug and Device Approvals - Hengrui Medicine announced that its injection of Rukang Qutuzumab has been included in the list of breakthrough therapy varieties, marking the 10th indication for this drug, aimed at treating locally advanced or metastatic non-small cell lung cancer patients with HER2 mutations [3]. - Shanghai Pharmaceuticals received approval for the listing application of the raw material drug Tamsulosin Hydrochloride, which is used for treating benign prostatic hyperplasia, with an investment of approximately RMB 1.5 million in its development [4]. Financial Reports - WuXi Biologics expects a 46.3% year-on-year increase in net profit for the full year 2025, projecting revenues of approximately RMB 21.79 billion and an adjusted net profit of about RMB 6.59 billion [5]. - Eucare Pharmaceuticals reported a 48.21% decline in net profit for 2025, with revenues of RMB 334 million, reflecting a 7.73% increase [6]. Capital Markets - Watson Bio plans to invest RMB 450 million to establish a biological industry investment fund with a target size of RMB 1 billion, focusing on synthetic biology and related sectors [7]. - Hite Bio intends to acquire a 23.08% stake in Beijing Shadong for RMB 62.02 million, increasing its ownership to 98.84% [8]. - Duorui Pharmaceuticals announced a partial tender offer to acquire 24.30% of its shares at a price of RMB 32.07 per share [9]. Industry Events - China's first C909 "airplane hospital" successfully completed its first in-flight surgery in Laos, providing medical services to over 600 patients since its launch [10]. - Researchers revealed the key mechanism of the "weight loss miracle drug" Semaglutide, showing its significant cartilage protection effects independent of weight loss, providing new drug development targets for metabolic osteoarthritis [11]. Public Sentiment Alerts - Shuyou Shen announced that its major shareholder, Xiangtang Group, has cumulatively reduced its holdings by 4.78 million shares, accounting for 1% of the total share capital [12].

Group 1: Board Election Announcement - The company announced the election of Mr. Zhao Yong as the employee representative director of the eighth board of directors, following the approval of the employee representative conference held on February 11, 2026 [1][3] - Mr. Zhao Yong meets the qualifications and conditions for the position as stipulated by relevant laws and the company's articles of association [1] - The number of directors who are also senior management and those who are employee representatives does not exceed half of the total number of directors, complying with legal requirements [1] Group 2: Stock Option Incentive Plan - The company reported that 680,000 stock options from the third exercise period of the 2019 A-share stock option incentive plan were available for exercise from February 8, 2025, to February 7, 2026 [5] - No stock options were exercised during the third exercise period, and the unexercised options will be canceled by the company [6][17] - The total share capital of the company as of the end of the third exercise period was 3,708,361,809 shares, and the lack of exercised options did not significantly impact the company's financial status [22] Group 3: Approval of Raw Material Drug - The company announced that its subsidiary, Shanghai Pharmaceutical Kangli, received approval from the National Medical Products Administration for the production of Tamsulosin hydrochloride [23][24] - Tamsulosin hydrochloride is a third-generation selective long-acting α1 blocker used for treating benign prostatic hyperplasia (BPH) [25] - The company has invested approximately RMB 1.5 million in research and development for this drug, which is expected to enhance its market presence [26]

Core Viewpoint - Shanghai Pharmaceuticals announced the approval of the production of Tamsulosin Hydrochloride raw material by the National Medical Products Administration, indicating a significant development in its product portfolio [1] Group 1: Company Developments - Shanghai Pharmaceuticals' subsidiary, Upjohn Kangli (Changzhou) Pharmaceutical Co., Ltd., received the approval notice for the marketing application of Tamsulosin Hydrochloride [1] - Tamsulosin Hydrochloride is a third-generation highly selective long-acting α1 inhibitor, used for the treatment of benign prostatic hyperplasia [1] Group 2: Product Background - The drug was developed by Japan's Yamanouchi Pharmaceutical and was approved for marketing by the U.S. Food and Drug Administration in July 1992 [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of Tamsulosin hydrochloride, a drug used to treat benign prostatic hyperplasia (BPH) [1] Group 1: Company Developments - The approval was granted to Shanghai Pharmaceuticals' subsidiary, Shanghai Pharmaceuticals Kangli (Changzhou) Pharmaceutical Co., Ltd. [1] - The company has invested approximately RMB 1.5 million in research and development for Tamsulosin hydrochloride [1] - The drug is a third-generation ultra-selective long-acting α1 inhibitor, originally developed by Japan's Yamanouchi Pharmaceutical and approved by the FDA in July 1992 [1] Group 2: Regulatory and Market Implications - The approval indicates that the raw material meets the regulatory requirements for domestic drug registration, allowing it to be sold in the domestic market [1] - This experience will be valuable for the company in future raw material drug applications [1] - The approval is not expected to have a significant impact on the company's current operating performance [1]

Core Viewpoint - Shanghai Pharmaceuticals (02607) has received approval from the National Medical Products Administration for the production of Tamsulosin hydrochloride, a drug used to treat benign prostatic hyperplasia (BPH) [1] Group 1: Company Developments - The approval for Tamsulosin hydrochloride indicates that the raw material meets domestic drug registration requirements and can be sold in the domestic market [1] - The company has invested approximately RMB 1.5 million in research and development for this drug [1] - The approval process has provided valuable experience for the company in future raw material drug applications [1] Group 2: Product Information - Tamsulosin hydrochloride is a third-generation ultra-selective long-acting α1 inhibitor, originally developed by Japan's Yamanouchi Pharmaceutical and approved by the FDA in July 1992 [1] - The company submitted the registration application for this drug to the National Medical Products Administration in July 2024, which was accepted [1] Group 3: Financial Impact - The approval of Tamsulosin hydrochloride is not expected to have a significant impact on the company's current operating performance [1]

Core Viewpoint - Shanghai Pharmaceuticals' subsidiary, Shanghai Kangli, has received approval from the National Medical Products Administration for the production of Tamsulosin Hydrochloride raw material, indicating a significant step in the company's product portfolio expansion [1] Group 1: Company Developments - Shanghai Kangli submitted a registration application for Tamsulosin Hydrochloride in July 2024, which has been accepted [1] - The company has invested approximately 1.5 million yuan in research and development for this product [1] Group 2: Market Context - The procurement amount for Tamsulosin Hydrochloride formulations in hospitals across mainland China is reported to be 413.8275 million yuan for 2024 [1] - The approval allows for domestic sales of the raw material, which may provide valuable experience for future applications, although it is not expected to significantly impact current performance [1]